Beersheva Mental Health Center
Quick facts
Marketed products
- testosterone gel (Androgel) · Endocrinology
Testosterone gel replaces deficient endogenous testosterone by transdermal absorption to restore normal androgen levels.
Phase 3 pipeline
- Amisulpride, Moclobemide · Psychiatry
This combination uses amisulpride (a dopamine D2/D3 antagonist) and moclobemide (a reversible monoamine oxidase-A inhibitor) to modulate dopaminergic and monoaminergic neurotransmission for psychiatric symptom management. - Bexarotene (Targretin LGD1069) · Oncology
Bexarotene is a retinoid X receptor (RXR) agonist that selectively activates RXR to promote differentiation and apoptosis of malignant T cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Beersheva Mental Health Center portfolio CI brief
- Beersheva Mental Health Center pipeline updates RSS
Frequently asked questions about Beersheva Mental Health Center
What are Beersheva Mental Health Center's marketed drugs?
Top marketed products include testosterone gel (Androgel).
What is Beersheva Mental Health Center's pipeline?
Beersheva Mental Health Center has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Amisulpride, Moclobemide, Bexarotene (Targretin LGD1069).
Related
- testosterone gel (Androgel) · Endocrinology
- Sector hub: All tracked pharma companies